In the KEYNOTE-059 phase II study of pembrolizumab in previously treated GC or GEJC, the ORR was 11.6%, with a longer median duration of response in PDL1+ patients (16.3 vs. 6.9 months) (150). The gene discussed is CD274; the disease is gastric cancer.